Back to top
more

Deciphera Pharmaceuticals (DCPH)

(Delayed Data from NSDQ)

$14.18 USD

14.18
527,033

-0.44 (-3.01%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $14.20 +0.02 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Deciphera Pharmaceuticals (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

by Zacks Equity Research

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen (AMGN) Up 2.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.33% and 9.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag

by Sundeep Ganoria

The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.

Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study

by Zacks Equity Research

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.

Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication

by Zacks Equity Research

FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.

Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation

by Zacks Equity Research

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.

Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.

BioCardia (BCDA) Up on Plans for Second Heart Failure Study

by Zacks Equity Research

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.

Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues

by Zacks Equity Research

Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 8.06% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 3.6% Since Last Earnings Report?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.